Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB): $23.21

0.15 (+0.65%)

POWR Rating

Component Grades














  • PACB scores best on the Quality dimension, with a Quality rank ahead of 46.01% of US stocks.
  • PACB's strongest trending metric is Stability; it's been moving up over the last 52 weeks.
  • PACB's current lowest rank is in the Stability metric (where it is better than 16.19% of US stocks).

PACB Stock Summary

  • With a price/sales ratio of 41.82, Pacific Biosciences Of California Inc has a higher such ratio than 94.58% of stocks in our set.
  • With a year-over-year growth in debt of 2,115.76%, Pacific Biosciences Of California Inc's debt growth rate surpasses 99.12% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PACB comes in at -26.47% -- higher than that of merely 12.06% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pacific Biosciences Of California Inc are RAMP, VUZI, FROG, GH, and MODN.
  • PACB's SEC filings can be seen here. And to visit Pacific Biosciences Of California Inc's official web site, go to

PACB Valuation Summary

  • PACB's price/sales ratio is 58.9; this is 1450% higher than that of the median Healthcare stock.
  • Over the past 132 months, PACB's price/sales ratio has gone down 570.5.
  • Over the past 132 months, PACB's price/sales ratio has gone down 570.5.

Below are key valuation metrics over time for PACB.

Stock Date P/S P/B P/E EV/EBIT
PACB 2021-08-31 58.9 24.1 -80.7 -93.4
PACB 2021-08-30 57.3 23.5 -78.5 -91.0
PACB 2021-08-27 56.6 23.2 -77.5 -90.0
PACB 2021-08-26 53.8 22.0 -73.7 -85.9
PACB 2021-08-25 54.7 22.4 -75.0 -87.2
PACB 2021-08-24 55.7 22.8 -76.3 -88.6

PACB Growth Metrics

  • The 5 year cash and equivalents growth rate now stands at 104.77%.
  • The 5 year revenue growth rate now stands at -2.93%.
  • Its 4 year revenue growth rate is now at -4.46%.
PACB's revenue has moved up $43,004,000 over the prior 33 months.

The table below shows PACB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 121.63 -93.735 -36.959
2021-06-30 105.825 -70.887 -77.209
2021-03-31 92.292 -78.964 -59.294
2020-12-31 78.893 19.503 29.403
2020-09-30 79.687 15.586 -45.623
2020-06-30 82.52 16.134 -51.038

PACB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PACB has a Quality Grade of C, ranking ahead of 52.82% of graded US stocks.
  • PACB's asset turnover comes in at 0.132 -- ranking 67th of 75 Measuring and Control Equipment stocks.
  • TMO, PKI, and PRPO are the stocks whose asset turnover ratios are most correlated with PACB.

The table below shows PACB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.427 -0.085
2021-03-31 0.169 0.412 -0.129
2020-12-31 0.271 0.413 0.185
2020-09-30 0.355 0.428 -0.409
2020-06-30 0.445 0.411 -0.473
2020-03-31 0.515 0.410 -0.412

PACB Price Target

For more insight on analysts targets of PACB, see our PACB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.75 Average Broker Recommendation 1.6 (Moderate Buy)

PACB Stock Price Chart Interactive Chart >

Price chart for PACB

PACB Price/Volume Stats

Current price $23.21 52-week high $53.69
Prev. close $23.06 52-week low $15.19
Day low $22.62 Volume 3,074,100
Day high $23.85 Avg. volume 2,967,090
50-day MA $25.84 Dividend yield N/A
200-day MA $29.26 Market Cap 5.12B

Pacific Biosciences of California, Inc. (PACB) Company Bio

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.

PACB Latest News Stream

Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream

Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about Pacific Biosciences Of California Inc that investors may wish to consider to help them evaluate PACB as an investment opportunity.

10 Reddit Stocks that Flopped in 2021

In this article, we discuss the 10 Reddit stocks that flopped in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Reddit Stocks that Flopped in 2021. Retail investors have taken the stock market by storm this year, pouring hundreds of millions into equities and developing a […]

Yahoo | November 26, 2021

After failed Illumina deal, new PacBio CEO builds for the long run and the short read

With $1 billion in the bank and an acquisition completed, this biotech pioneer is hunting for more deals in DNA sequencing. "Scale matters," says the new CEO.

Yahoo | November 22, 2021

PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

Yahoo | November 22, 2021

Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company’s Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Co

Yahoo | November 22, 2021

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity I

Yahoo | November 19, 2021

Read More 'PACB' Stories Here

PACB Price Returns

1-mo -16.15%
3-mo -26.27%
6-mo -11.14%
1-year 29.30%
3-year 196.80%
5-year 236.38%
YTD -10.52%
2020 404.67%
2019 -30.54%
2018 180.30%
2017 -30.53%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7721 seconds.